Top Markets
Coin of the day
Oncotelic Therapeutics, Inc. Oncotelic Therapeutics, Inc.

Oncotelic Therapeutics, Inc.

OTLC
Rang in Aktien #30395
Oncotelic Therapeutics, Inc., an Agoura Hills, California-based clinical-stage... Oncotelic Therapeutics, Inc., an Agoura Hills, California-based clinical-stage biopharmaceutical company, specializes in developing therapeutics for rare oncological conditions. Its flagship therapeutic candidate, OT-101 – an antisense compound designed to inhibit TGF-ß2 – is currently undergoing Phase 3 clinical trials for both pancreatic cancer and glioblastoma. Beyond oncology, OT-101 is also being explored for its potential in treating various viral diseases, including severe acute respiratory syndrome (SARS) and coronaviruses. The company's pipeline further includes OXi4503, which is being advanced for acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), and CA4P, intended for the treatment of advanced metastatic melanoma.
Aktienkurs
$0.03834
Zuletzt synchronisiert: 2026-08-18
Marktkapitalisierung
$17.01M
Veränderung (1 Tag)
-4.15%
Veränderung (1 Jahr)
-24.82%
Land
US
Handel Oncotelic Therapeutics, Inc. (OTLC)

Kategorie

Dividendenrendite-Verlauf für Oncotelic Therapeutics, Inc. (OTLC)
Dividendenrendite (TTM) von Oncotelic Therapeutics, Inc. (Aktienkürzel: OTLC) zum 2026: 0
Durchschnittliche Dividendenrendite der letzten 5 Jahre: 0.00%
Dividendenrendite-Verlauf für Oncotelic Therapeutics, Inc. (OTLC) von 2026 bis 2026
Dividendenrendite am Ende jedes Jahres (TTM)
Jahr Dividendenrendite ändert
Nicht genügend Daten für die angegebenen Daten.
Dividendenrenditen (TTM) für ähnliche Unternehmen oder Wettbewerber
Unternehmen Dividendenrendite Land
0.00%
US
0.00%
NL
3.12%
AU
0.00%
CH
0.48%
BE